ReviewNature reviews. Clinical oncology2015
Opportunities and challenges of radiotherapy for treating cancer.
Review in Nature reviews. Clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 353 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer
Phase 1 Feasibility and Safety of Whole Heart Radiotherapy for End-stage Heart Failure: First In-human Treatments
Who cites it
353 citing papers in PubMed, 2 syntheses or guidelines pooled it, 743 citations in OpenAlex.
- Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges.International journal of molecular sciences · 2026Pooled it
- Nonlinear duration-efficacy association of neoadjuvant PD-1/PD-L1 blockade with chemoradiotherapy in pMMR/MSS locally advanced rectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Evaluating Image Quality of Cone Beam Computed Tomography Using HyperSight® on the Varian TrueBeam.Annals of biomedical engineering · 2026Article
- Review
- Routine Inflammatory and Hematological Markers and Acute Radiation Toxicity in Patients with Prostate Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Programmed Clonal Expansion Associated with V(D)J Recombination Drives an ATM-Dependent Vulnerability Underlying Preferential Lymphocyte Depletion and Myeloid Bias Following DNA Damage.bioRxiv : the preprint server for biology · 2026Article
- Radiobiological effects of flattening filter and flattening filter free radiotherapy x-ray on inflammatory and apoptotic pathways in cardiac and pulmonary tissues in an MCF-7 xenograft breast cancer model.Journal of radiation research · 2026Article
- Beyond apoptosis: nanomedicine enabled reprogramming of tumor cell death for next-generation radiosensitization.Journal of nanobiotechnology · 2026Review
- DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer.Cancer research · 2026Article
- Multiphasic blood transcriptomic signatures of radioprotection by BIO 300, a synthetic genistein nanosuspension, in a nonhuman primate model of acute radiation syndrome.Journal of translational medicine · 2026Article
- HMGB1 promotes radiotherapy resistance in human cervical cancer HeLa cells through regulating the AMPK/mTOR signaling.World journal of surgical oncology · 2026Article
- Nonlinear Redox-Immune Coupling Under Low-Dose-Rate Radiation: A Compartment-Specific Framework for Biological Responses-A Narrative Review.Antioxidants (Basel, Switzerland) · 2026Review
- From Cellular Radiosensitivity to Precision Radiotherapy: Integrating Functional Assays, Genomics, and Clinical Modeling.Cancers · 2026Review
- Fuzuloparib enhances radiosensitivity of gain-of-function mutant p53 R273H NSCLC by promoting SLC7A11/GSH/GPX4 axis mediated ferroptosis.NPJ precision oncology · 2026Article
- Engineered artificial antigen-presenting cells for tumor immunotherapy: Design strategies, clinical applications, and translational challenges.Materials today. Bio · 2026Review
- MonoHER selectively enhances the radiotherapy response in p53 wild-type breast cancer via stabilization of p53.Clinical and translational radiation oncology · 2026Article
- Self-assembled nanoplatforms for cancer immunotherapy: Principles, progress and perspectives.Acta pharmaceutica Sinica. B · 2026Review
- Current evidence and strategies for bridging therapy in CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphomas.Annals of hematology · 2026Review
- CXCR5Nature communications · 2026Article
- [Daily online adaptive irradiation of bladder tumors with individualized safety margin creation].Magyar onkologia · 2026Article
293 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The past 20 years have seen dramatic changes in the delivery of radiation therapy, but the impact of radiobiology on the clinic has been far less substantial. A major consideration in the use of radiotherapy has been on how best to exploit differences between the tumour and host tissue characteristics, which in the past has been achieved empirically by radiation-dose fractionation. New advances are uncovering some of the mechanistic processes that underlie this success story. In this Review, we focus on how these processes might be targeted to improve the outcome of radiotherapy at the individual patient level. This approach would seem a more productive avenue of treatment than simply trying to increase the radiation dose delivered to the tumour.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.